Weight-loss drug cuts risk of heart attack, strokes: Novo Nordisk

COPENHAGEN - Shares in Danish pharma group Novo Nordisk soared to a record high on Tuesday after a late-stage trial suggested its obesity drug Wegovy could reduce the risk of heart attacks or stroke by 20 percent.

Preliminary results showed that patients taking Wegovy had a 20 percent lower risk of suffering from a heart attack or stroke compared to those who took a placebo, Novo Nordisk said in a statement.

"We are very excited about the results," the company's executive vice president for development Martin Holst Lange said, adding the drug "has the potential to change how obesity is regarded and treated."

Novo Nordisk's share price closed up by more than 17 percent on the Copenhagen stock exchange on Tuesday.

The medical community also welcomed the results.

While the trials "still need to be confirmed through careful peer review, they demonstrate the urgent need for patients living with obesity to be offered this effective and safe drug to prevent future disease," said Simon Cork, senior lecturer in physiology at Anglia Ruskin University.

"This will not only provide significant financial savings for health bodies, but provide people with a greater quality of life," he said.

Novo Nordisk, the world's biggest insulin maker which manufactures both Wegovy and diabetes drug Ozempic, in May announced a 39 percent rise in its first-quarter profit, buoyed by sales of its obesity treatments.

In mid-July, the Amsterdam-based European Medicines Agency said it was reviewing data "on the risk of suicidal thoughts and thoughts of self-harm" with three popular weight-loss drugs, Ozempic and Wegovy -- which both have semaglutide as their main ingredient -- and Saxenda, whose main ingredient is liraglutide.

The detailed results of the trial will be presented at a scientific conference later this year, Novo Nordisk said, adding that it plans to apply for regulatory approval to expand the uses for Wegovy in the US and the EU in 2023.

Competition among pharmaceutical groups over obesity treatments is fierce, with more than a billion people in the world suffering from obesity, according to the World Health Organization.

Agence France-Presse

Diet and exercise may help maintain weight loss

NEW YORK - Programs focused on both diet and exercise may help people who have lost weight keep the pounds from creeping back on, according to a new analysis of past studies.

Orlistat, an obesity drug, may also be effective when taken at higher doses, researchers found.

More than one third of US adults are obese, and obesity raises the risk of heart disease, type 2 diabetes and some types of cancer. Losing weight - and keeping it off - can reduce those risks.

“Long term weight loss through changes in eating and physical activity is possible, even in adults who have already acquired obesity related illness, and effective weight loss programs are now available,” researchers led by Stephan Dombrowski of Newcastle University in the UK write.

They pooled data from 45 studies that included a total of 7,788 adults who had lost at least 5% of their body weight. The studies looked at people’s ability to keep the weight off for a minimum of one year.

Forty-two of the studies included an initial phase meant to produce weight loss. The participants in those studies lost an average of about 24 pounds.

The studies all looked at medication or lifestyle changes such as diet, physical activity and meal replacements, either alone or in combination, to help with weight loss maintenance.

The researchers found that people participating in programs that combined diet and exercise gained back 3.4 fewer pounds after one year compared to people receiving no extra help with weight maintenance or standard treatment only.

They also found that combining Orlistat with behavioral changes resulted in 4 fewer pounds regained after one year compared to participants who took a drug-free placebo.

Orlistat appeared to be more effective at larger doses, according to results published in the British medical journal BMJ. But the drug also came with gastrointestinal side effects.

Lori Rosenthal said the findings echo previous research and that it was “interesting” that the authors included data from so many studies.

Rosenthal is a dietician at Montefiore Medical Center in Bronx, New York. She was not involved in the new review.

“I think it’s great that they covered so many different studies but there’s also so much variety and the long-term research isn’t there, you know - going beyond 24 months,” she told Reuters Health.

Still, “We know that interventions like diet and physical activity are really important in preventing weight regain after losing,” she said.

Rosenthal noted that participants who had dropped out of the programs were not always included in the findings, and that could affect the review’s results.

“Weight management is hard,” she said. “People have to realize that it’s not just the losing it - it’s for life, and if you don’t like what you’re doing, if it doesn’t work for you, you’re not going to stick with it.”

Support during the weight management phase is important, Rosenthal added. There are support groups and dietitians who can give people tricks and tools to help make it easier, she said.

She offered some advice for people who have lost weight and are moving into a maintenance phase.

“It’s really important to remember that weight management is a mind and a stomach game,” she said. “You have to feel good about what you’re having.”

“Really make sure you find foods you like - that you’re choosing foods not because you’re on a diet but because you like them,” Rosenthal said. “You have to like them more than the other things you were eating before.”

Rosenthal said that if people don’t like the new foods they eat or their new routine, they will be more likely to go right back to old habits.

She said being mindful and chewing slowly also allows people to enjoy their food and eat less.

source: www.abs-cbnnews.com